

## STATEMENT

Of Prof. Dr. Nadka Boyadzhieva, MSc PHD  
Department of pharmacology and toxicology of Medical Faculty,  
Medical University – Sofia

Referring to the work of Dr. I. Ivanov and Dr. V. Yordanov – medical oncologists in the Complex Oncological Center – Ruse on topic: “Comparative clinical-laboratory observations regarding the preventative, stimulating and normalizing effect of the nutrient additive MAOLO on the hemopoiesis, in patients with oncological diseases, undergoing chemotherapy and a comparative preparation marked for the purpose with the signature SGN”.

The written material suggested for a statement with results from investigations of product MAOLO (nutrient additive) is in volume of 4 machine pages and attended with a booklet containing statements of various clinics/hospitals of the tests with this product. During the analysis of the materials, the following conclusions can be made:

1. The researchers from Ruse have the objective to enrich the information published about the product MAOLO with the opportunities to maintain within limits the blood indicators – leucocytes, thrombocytes, hemoglobin and neutrophils.

2. MAOLO falls within the category of “nutrient additives” and is not a medication. This product has no claim to heal. The team of doctors has emphasized this from the very beginning.

3. The researchers have set as an objective to select on a random principle patients of three nosological units, with values of the referred hemo-indicators around the lower referent limit. **Colorectal carcinoma; Mammal gland carcinoma and Lung carcinoma.** They distribute the patients in two flows. One for application of MAOLO and the other one with comparable control preparation with the random signature SGN which has “composition and form allowing the comparative study with MAOLO”. They do not reveal the composition and details about the control preparation, which explains the lack of discussion on it in this statement.

4. The results from the investigation confirm the declared designation of the product MAOLO for the normalization of the blood indicators – leucocytes, thrombocytes, hemoglobin and neutrophils.
5. The team has not strictly followed the rules for clinical tests of new drugs which is admissible because MAOLO is a nutrient additive. The comparative study of MAOLO is positive which underlines the extent of product efficiency.
6. An important element of the investigation are the results that the product MAOLO is not harmful which correlates with the toxicological information about MAOLO which is public and can be found on the site for this product. The toxicological investigation has been performed in the Pharmaceutical faculty – Sofia by a respectful and experienced team leader by Prof. Danchev. The results demonstrate, both in view of the experimental studies and the clinical studies, that MAOLO is a non-toxic means.
7. There are little comparative clinical observations of nutrient additives which gives advantage to the product MAOLO via the results of the reviewed comparative investigations. The reference is important for patients and doctors. The results give grounds to make a conclusion that the product MAOLO is with proven effectiveness and harmlessness.
8. The analysis of the composition and technology of preparation of product MAOLO gives us ground to admit that its effect is due to both active substances in the plants (12 as a number) and the special technology of preparation and preservation of the active substances ensuring action and efficiency of this nutrient additive.

As a conclusion: Product MAOLO is an efficient and harmless means (nutrient additive) for patients before, during and after chemotherapy and radiation treatment which improves the hemopoiesis and is beneficial for the performing of cytotoxic therapy. The results give ground to assume that MAOLO can provide prevention of bone marrow in radiation and chemotherapy.

Signature, seal [MEDICAL UNIVERSITY – SOFIA, MEDICAL FACULTY,  
DEPARTMENT FOR PHARMACOLOGY AND TOXICOLOGY]

Written by: Prof. Dr. Nadka Boyadzhieva, MSc PHD  
Date 12.11.2019, Sofia